A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 14, 2025

Primary Completion Date

August 30, 2028

Study Completion Date

August 30, 2028

Conditions
Fabry Disesase
Interventions
DRUG

HM15421/GC1134A

SC

Trial Locations (10)

15224

RECRUITING

University of Pittsburgh Medical Center Children's Hoispital of Pittsburgh, Pittsburgh

22030

RECRUITING

Lysosomal and Rare Disorders Research and Treatment Center, Fairfax

50612

RECRUITING

Pusan National University Children's Hospital in Yangsan, Yangsan

55455

RECRUITING

University of Minnesota, Minneapolis

90095

RECRUITING

David Geffen School of Medicine UCLA, UCLA Health, Los Angeles

66160-8500

RECRUITING

University of Kansas School of Medicine, Kansas City

45229-3039

RECRUITING

Children's Hospital Medical Center, Cincinnati

S2000

RECRUITING

Centro Medico IPAM, Rosario

C1199ABB

RECRUITING

Hospital Italiano de Buenos Aires, Buenos Aires

03722

RECRUITING

Yonsei University, College of Medicine, Seoul

Sponsors
All Listed Sponsors
collaborator

Hanmi Pharmaceutical Company Limited

INDUSTRY

lead

GC Biopharma Corp

INDUSTRY